Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Elucidating biomarkers of prognosis of 177Lu-PSMA-617-based therapy

Anis Hamid, MBBS, Dana-Farber Cancer Institute, Boston, MA, discusses data from the phase I PRINCE trial (NCT03658447), which investigated 177Lu-PSMA-617 plus pembrolizumab for patients with metastatic castration resistant prostate cancer (mCRPC). Circulating tumour cells (CTCs) were found to correlate with patient outcomes, where levels of CTCs declined when patients had favorable outcomes 12 weeks after treatment. PSMA positron emission tomography (PET) metrics such as tumor volume were additionally associated with patient outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.